Literature DB >> 28878527

Cutaneous Larva Migrans.

Richie Manikat1, Saman Kannangara2.   

Abstract

Entities:  

Year:  2017        PMID: 28878527      PMCID: PMC5572199          DOI: 10.4103/jgid.jgid_171_16

Source DB:  PubMed          Journal:  J Glob Infect Dis        ISSN: 0974-777X


× No keyword cloud information.
Sir, Cutaneous larva migrans is a characteristic serpiginous skin lesion which may be seen in travelers. The most common causative organisms are Ancylostoma braziliense and Ancylostoma caninum.[1] A 49 year-old male presented to the office complaining of a rash on his legs. The patient had recently spent 5 days in Florida moving lemon trees. Five days after returning to his home in eastern Pennsylvania, the patient noticed a rash on both legs. Examination showed multiple red, raised, serpiginous lesions on his lower legs [Figure 1]. The patient was started on ivermectin orally for 2 days. He was reevaluated after 3 weeks. The rash had improved significantly, the serpiginous lesions were fading, and pruritus had disappeared [Figure 2].
Figure 1

Pretreatment

Figure 2

Posttreatment

Pretreatment Posttreatment Cutaneous larva migrans is most commonly associated with animal hookworms. The infection is frequently seen in the Southeastern United States. The diagnosis is clinical. Antihelminthic therapy with ivermectin or albendazole is frequently curative.[2]

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  2 in total

1.  One-week therapy with oral albendazole in hookworm-related cutaneous larva migrans: a retrospective study on 78 patients.

Authors:  Stefano Veraldi; Silvia Bottini; Gaetano Rizzitelli; Maria Chiara Persico
Journal:  J Dermatolog Treat       Date:  2011-02-06       Impact factor: 3.359

2.  Hookworm-related cutaneous larva migrans acquired in the UK.

Authors:  Katy Baple; James Clayton
Journal:  BMJ Case Rep       Date:  2015-11-13
  2 in total
  1 in total

1.  Global output of research on epidermal parasitic skin diseases from 1967 to 2017.

Authors:  Waleed M Sweileh
Journal:  Infect Dis Poverty       Date:  2018-08-06       Impact factor: 4.520

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.